Furthermore, in 2022, Chen et al. found that berberine acts as a direct MET inhibitor, playing a pivotal role in the treatment of non-small cell lung cancer (NSCLC) (Chen et al., 2022). The gene discussed is MET; the disease is non-small cell lung carcinoma.